Moxalactam (LY127935) in treatment of meningitis due to gram-negative bacilli

J. F. Fisher, M. J. Carter, J. Parsons, J. P. Rissing

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Moxalactam (LY127935; 6059S), a new broad-spectrum β-lactam antibiotic, was used successfully with an aminoglycoside in a patient with Serratia marcescens meningitis complicating a neurosurgical procedure. With a bioassay method, peak and trough serum and cerebrospinal fluid concentrations of moxalactam were determined during therapy. Mean peak and trough serum levels wer 100.6 and 35.5 μg/ml, respectively. corresponding mean peak and trough cerebrospinal fluid levels were 12.4 and 10.38 μg.ml. Cerebrospinal fluid levels of moxalactam exceeded the minimal bactericidal concentration for the infecting organism by more than 30-fold throughout therapy. No untoward effects of moxalactam were observed. Moxalactam may be useful agent in the treatment of meningitis due to susceptible gram-negative bacilli.

Original languageEnglish (US)
Pages (from-to)218-221
Number of pages4
JournalAntimicrobial Agents and Chemotherapy
Volume19
Issue number2
DOIs
StatePublished - Jan 1 1981

Fingerprint

Moxalactam
Meningitis
Bacillus
Cerebrospinal Fluid
Therapeutics
Neurosurgical Procedures
Lactams
Serratia marcescens
Aminoglycosides
Serum
Biological Assay
Anti-Bacterial Agents

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Moxalactam (LY127935) in treatment of meningitis due to gram-negative bacilli. / Fisher, J. F.; Carter, M. J.; Parsons, J.; Rissing, J. P.

In: Antimicrobial Agents and Chemotherapy, Vol. 19, No. 2, 01.01.1981, p. 218-221.

Research output: Contribution to journalArticle

@article{906cd331fce040398811bc9130b521b0,
title = "Moxalactam (LY127935) in treatment of meningitis due to gram-negative bacilli",
abstract = "Moxalactam (LY127935; 6059S), a new broad-spectrum β-lactam antibiotic, was used successfully with an aminoglycoside in a patient with Serratia marcescens meningitis complicating a neurosurgical procedure. With a bioassay method, peak and trough serum and cerebrospinal fluid concentrations of moxalactam were determined during therapy. Mean peak and trough serum levels wer 100.6 and 35.5 μg/ml, respectively. corresponding mean peak and trough cerebrospinal fluid levels were 12.4 and 10.38 μg.ml. Cerebrospinal fluid levels of moxalactam exceeded the minimal bactericidal concentration for the infecting organism by more than 30-fold throughout therapy. No untoward effects of moxalactam were observed. Moxalactam may be useful agent in the treatment of meningitis due to susceptible gram-negative bacilli.",
author = "Fisher, {J. F.} and Carter, {M. J.} and J. Parsons and Rissing, {J. P.}",
year = "1981",
month = "1",
day = "1",
doi = "10.1128/AAC.19.2.218",
language = "English (US)",
volume = "19",
pages = "218--221",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "2",

}

TY - JOUR

T1 - Moxalactam (LY127935) in treatment of meningitis due to gram-negative bacilli

AU - Fisher, J. F.

AU - Carter, M. J.

AU - Parsons, J.

AU - Rissing, J. P.

PY - 1981/1/1

Y1 - 1981/1/1

N2 - Moxalactam (LY127935; 6059S), a new broad-spectrum β-lactam antibiotic, was used successfully with an aminoglycoside in a patient with Serratia marcescens meningitis complicating a neurosurgical procedure. With a bioassay method, peak and trough serum and cerebrospinal fluid concentrations of moxalactam were determined during therapy. Mean peak and trough serum levels wer 100.6 and 35.5 μg/ml, respectively. corresponding mean peak and trough cerebrospinal fluid levels were 12.4 and 10.38 μg.ml. Cerebrospinal fluid levels of moxalactam exceeded the minimal bactericidal concentration for the infecting organism by more than 30-fold throughout therapy. No untoward effects of moxalactam were observed. Moxalactam may be useful agent in the treatment of meningitis due to susceptible gram-negative bacilli.

AB - Moxalactam (LY127935; 6059S), a new broad-spectrum β-lactam antibiotic, was used successfully with an aminoglycoside in a patient with Serratia marcescens meningitis complicating a neurosurgical procedure. With a bioassay method, peak and trough serum and cerebrospinal fluid concentrations of moxalactam were determined during therapy. Mean peak and trough serum levels wer 100.6 and 35.5 μg/ml, respectively. corresponding mean peak and trough cerebrospinal fluid levels were 12.4 and 10.38 μg.ml. Cerebrospinal fluid levels of moxalactam exceeded the minimal bactericidal concentration for the infecting organism by more than 30-fold throughout therapy. No untoward effects of moxalactam were observed. Moxalactam may be useful agent in the treatment of meningitis due to susceptible gram-negative bacilli.

UR - http://www.scopus.com/inward/record.url?scp=0019796435&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019796435&partnerID=8YFLogxK

U2 - 10.1128/AAC.19.2.218

DO - 10.1128/AAC.19.2.218

M3 - Article

C2 - 6214985

AN - SCOPUS:0019796435

VL - 19

SP - 218

EP - 221

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 2

ER -